Royal Medical Center review

Royal Medical Center looks like a clinically serious hormone practice, and its storefront shows its prices. Its founder, Dr. Dagoberto Rodriguez, has practiced in Florida since 1990 after an Emory residency; its testosterone protocol pairs testosterone with a testicular stimulant and an estrogen blocker at $195 a month all-inclusive; its peptides are named and priced, sermorelin at $175 a month; and it names Belmar Pharma Solutions as its dispensing pharmacy. The catch is breadth. The same shelf sells BPC-157, TB-500 and blends built on them at $200 a month — peptides the FDA kept on its compounding safety-risk list until April 2026 and has not yet cleared for pharmacy compounding — so the catalog's range is not a proxy for its evidence.

Royal Medical Center is a physician-led hormone practice based in Deerfield Beach, Florida, founded by Dr. Dagoberto Rodriguez, MD — Emory residency, in practice since 1990, formerly a department chairman at Coral Springs Medical Center, and a teacher of University of Miami family-practice residents, with his Florida license number published. Its catalog spans testosterone replacement for men, hormone therapy for women, compounded GLP-1 weight loss, ED medications and a large injectable peptide shelf: sermorelin acetate, tesamorelin alone and with ipamorelin, two CJC-1295/ipamorelin strengths, hexarelin, IGF-1 LR3, AOD, MOTS-c, BPC-157, TB-500, GHK-Cu, PT-141, named blends such as KLOW, ATLAS, Wolverine and Glow, plus NAD⁺ and glutathione injections.

A consultation-first model with all-inclusive program pricing. Its own steps are a comprehensive lab panel, a medical-history review, a physical examination and a physician consultation, after which a personalized program is shipped from the pharmacy; the testosterone program repeats labs 90 days after you start and physical exams annually. The testosterone protocol is its most clinically literate feature — testosterone plus a testicular stimulant listed as clomiphene, enclomiphene or gonadorelin, plus an estrogen blocker — because it addresses the two predictable consequences of exogenous testosterone, testicular suppression and aromatization, instead of ignoring them; hCG is offered where labs support it. Disclosure is solid on several points. The footer names Belmar Pharma Solutions as the dispensing pharmacy, the practice publishes a street address and phone number, the site displays a LegitScript seal, and its product pages carry a plain compounding disclaimer that the FDA does not verify the safety, effectiveness or quality of compounded drugs. What is missing: no operating legal entity, no state list beyond a storefront filter by state, and no refund, cancellation or insurance policy anywhere. The storefront also sits behind a bot check that can take a few seconds to clear. It advertises a guarantee to beat any competitor's price by 25%, which is a sales promise rather than something a reader can price in advance.

Published per product, with one- and two-month prices on most peptides. Sermorelin acetate is $175 for one month or $325 for two. Tesamorelin/ipamorelin is $250 for one month or $450 for two, specified as a 6 ml vial at 1 mg/0.5 mg per ml. Tesamorelin alone, CJC-1295/ipamorelin at the lower strength, hexarelin, BPC-157, TB-500, GHK-Cu and PT-141 are each listed at $200 a month, with BPC-157 and TB-500 at $350 for two months; injectable NAD⁺ is $175 and glutathione $139, which is the "peptide therapy starting at $139" figure on the homepage. On the hormone side, the all-inclusive testosterone program is $195 a month covering shipping, doctor consultations, medication and supplies, and a testosterone-only tier is $89 a month without the stimulant and blocker; enclomiphene and clomiphene are $150 and hCG $225. Compounded GLP-1 starts at $67 a month, a weight-loss figure that says nothing about peptide pricing. Before paying, confirm what the peptide price includes — the product pages list the vial, not the consultation or labs — and how often testosterone labs repeat after the first 90 days.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The practice names Belmar Pharma Solutions as its dispensing pharmacy and states on its product pages that the FDA does not verify the safety, effectiveness or quality of compounded drugs; compounded sterile preparations are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, this catalog spans the full range from well-supported to essentially unstudied, and the flat $200 price point does not tell you which is which. Testosterone replacement has a large randomized base including a cardiovascular safety trial, and needs ongoing hematocrit, PSA and testosterone monitoring. Enclomiphene and clomiphene raise endogenous testosterone by blocking estrogen feedback at the pituitary and preserve fertility, but are not FDA-approved for that use in men; gonadorelin is a GnRH analog used to maintain testicular signaling on testosterone therapy, with a sound rationale and thin comparative outcome data. Sermorelin is a GHRH analog with a real mechanism and thin long-term outcome data. Tesamorelin is the outlier in the growth-hormone family with genuine randomized evidence — its approved label is for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, and use outside that indication is off-label. Ipamorelin is a ghrelin-receptor secretagogue with essentially no controlled human outcome trials. BPC-157 and TB-500 have animal literature and no controlled human outcome trials, and neither is an FDA-approved drug; the FDA kept both on its list of bulk substances that may present significant safety risks until April 2026, citing immunogenicity risk and little or no human safety information, and neither is yet on the list of substances pharmacies may compound. PT-141 is approved only for acquired, generalized hypoactive sexual desire disorder in premenopausal women; anything else is off-label. GHK-Cu has essentially no controlled human outcome data. Individual results vary.